
T2 Biosystems to Exhibit Rapid and Sensitive Assay for Sepsis Pathogens at IDWeek 2013



T2 Biosystems, a company developing direct detection products enabling superior diagnostics, announced that it will provide demonstrations of its flagship test, T2Candida®, for the rapid and sensitive identification of species-specific Candida directly from whole blood, on its T2Dx® instrument at Booth #922 at IDWeek 2013, October 2-6, 2013, in San Francisco, CA. Without the need for blood culture, T2Candida directly detects five species of Candida in a whole blood specimen in approximately 3 hours with a limit of detection as low as 1 CFU/mL. The T2Candida test is currently being evaluated in a pivotal clinical trial, and results will be available in the first half of 2014.

T2Candida has the potential to address a significant health threat as described in the recently published report on Antimicrobial Resistant Threats in the United States, 2013 by the U.S. Department of Health and Human Services through the Centers for Disease Control and Prevention, which places Candida in the Serious Hazard Level category. As a Serious Threat, the CDC warns that ongoing monitoring and prevention is necessary to prevent Candida from becoming an Urgent Hazard.

The T2Candida assay is run on the T2Dx instrument, which utilizes the Company's T2MR® technology. T2MR uses miniaturized magnetic resonance to directly detect any immunodiagnostic, molecular or hemostasis target from complex clinical samples, such as whole blood, plasma, serum, sputum and urine.

Source: [T2 Biosystems](#)

Published on : Mon, 30 Sep 2013